Company Encyclopedia
View More
name
Bio-Path
BPTH.US
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).
1.946 T
BPTH.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bio-Path Holdings Delays Quarterly Financial Report

    Bio-Path Holdings Inc. announced a delay in filing its quarterly financial report for the period ending September 30, 2025, due to a change in management. The company expects to file the report within the allowed extension period.

    Reuters·
    US
    BPTH
    0.00%
    Reuters·
    US
    BPTH
    0.00%

    Bio-Path Holdings Seeks Financing for Strategic Turnaround

    Bio-Path Holdings is seeking financing for a strategic turnaround, including updating their finance team, engaging new auditors, hiring investment bankers, and pursuing mergers and acquisitions. The company faces uncertainty in raising capital, impacting operations and public listing. Analysts rate BPTH stock as a Buy with a $2.00 target, but AI Analyst Spark rates it as Underperform due to poor financial performance and bearish technical indicators.

    Tip Ranks·
    US
    BPTH
    0.00%
    Tip Ranks·
    US
    BPTH
    0.00%

    Bio-Path Holdings Announces Board Resignation Amid Turnaround Efforts

    Bio-Path Holdings Inc. announced the resignation of Douglas Morris from its Board of Directors, effective November 13, 2025. The company is seeking financing for a turnaround, which includes updating its finance team and exploring strategic options like portfolio sales, partnerships, or mergers and acquisitions.

    Reuters·
    US
    BPTH
    0.00%
    Reuters·
    US
    BPTH
    0.00%

    Bio-Path Holdings Announces Executive and Board Changes

    Bio-Path Holdings, Inc. announced on October 22, 2025, the appointment of Vikram Grover as President, CEO, CFO, and Board member, following the resignations of Douglas Morris and Paul Aubert from their roles. The changes are effective immediately, with Grover taking over the leadership positions. The reasons for the resignations were not disclosed. This information was filed with the SEC under the original filing BIO-PATH HOLDINGS, INC. [ BPTH ] - 8-K - Oct. 29, 2025.

    TradingView·
    US
    BPTH
    0.00%
    TradingView·
    US
    BPTH
    0.00%

    Bio-Path | 10-Q: FY2025 Q2 EPS: USD -0.55

    LB filings·
    US
    BPTH
    0.00%
    LB filings·
    US
    BPTH
    0.00%
    © 2025 Longbridge｜Disclaimer